ASH: Tes­sa Ther­a­peu­tic­s' next-gen cell ther­a­py clears four pa­tients' tu­mors in ear­ly study

Tes­sa Ther­a­peu­tics is do­ing CAR-T a bit dif­fer­ent­ly. Af­ter read­ing out some pos­i­tive — al­beit ear­ly — re­sults back in May show­ing their virus-spe­cif­ic T cells (VSTs) achieved three par­tial re­spons­es in pa­tients with CD30-pos­i­tive lym­phomas, the com­pa­ny now says the fuller pic­ture looks even brighter.

TT11x, Tes­sa’s “off the shelf” CD30.CAR-mod­i­fied Ep­stein-Barr virus-spe­cif­ic T-cell (EBVST) ther­a­py, achieved a 77.8% over­all re­sponse rate (7 of 9 pa­tients) in a Phase I tri­al, the Sin­ga­pore-based com­pa­ny an­nounced at this year’s ASH con­fer­ence. What’s more, four of those sev­en pa­tients saw a com­plete re­sponse, Tes­sa said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER